Famotidine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00927 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 41 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | duodenogastric reflux | KG + DL |
| 2 | duodenal obstruction | KG + DL |
| 3 | active peptic ulcer disease | KG + DL |
| 4 | peptic ulcer perforation | KG + DL |
| 5 | gastrojejunal ulcer | KG + DL |
| 6 | abnormality of glucagon secretion | KG + DL |
| 7 | gastroduodenitis | KG + DL |
| 8 | peptic ulcer disease | KG + DL |
| 9 | multiple endocrine neoplasia | KG + DL |
| 10 | acne (disease) | KG + DL |
| 11 | Smouldering systemic mastocytosis | KG + DL |
| 12 | leather-bottle stomach | KG + DL |
| 13 | duodenitis | KG + DL |
| 14 | lymphoadenopathic mastocytosis with eosinophilia | KG + DL |
| 15 | systemic mastocytosis | KG + DL |
| 16 | pancreas disease | KG + DL |
| 17 | nephrogenic syndrome of inappropriate antidiuresis | KG + DL |
| 18 | hyperglycemia | KG + DL |
| 19 | neoplastic syndrome | KG + DL |
| 20 | stomach disease | KG + DL |
| 21 | intraepithelial neoplasia | KG + DL |
| 22 | acrogeria | KG + DL |
| 23 | achlorhydria | KG + DL |
| 24 | hiatus hernia (disease) | KG + DL |
| 25 | oral mucosa leukoplakia | KG + DL |
| 26 | pylorospasm | KG + DL |
| 27 | gastric dilatation | KG + DL |
| 28 | cascade stomach | KG + DL |
| 29 | Dieulafoy lesion | KG + DL |
| 30 | hereditary mucosal leukokeratosis | KG + DL |
| 31 | eosinophilic esophagitis | KG + DL |
| 32 | esophageal atresia (disease) | KG + DL |
| 33 | esophageal leukoplakia (disease) | KG + DL |
| 34 | dyskinesia of esophagus | KG + DL |
| 35 | hemorrhagic duodenitis | KG + DL |
| 36 | esophageal tuberculosis | KG + DL |
| 37 | esophageal diverticulosis | KG + DL |
| 38 | esophageal malformation | KG + DL |
| 39 | Ehlers-Danlos syndrome, kyphoscoliotic and deafness type | KG + DL |
| 40 | hypoalphalipoproteinemia | KG + DL |
| 41 | nephrogenic diabetes insipidus | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.